Longevity Science — 2026-10-31
This week’s longevity research highlights include a new anti-senescence vaccine that increased mouse lifespan by 12%, and a comprehensive market report projecting the epigenetic reprogramming sector to reach $16.14 billion. Industry developments feature significant NIH funding for the Dog Aging Project and new FDA clearances for AI-driven Alzheimer's risk assessment tools.
Longevity Science — 2026-10-31
Top Research Findings
Anti-Senescence Vaccine Increases Mouse Lifespan A new study from the Lifespan Research Institute reports that late-life treatment with a three-element senolytic vaccine led to lower senescence markers and a 12% increase in median lifespan in female B6 mice. The study suggests that helping the immune system kill "zombie cells" (senescent cells) can significantly impact aging outcomes, though short-lived controls complicate the broader picture.
Epigenetic Reprogramming Market Growth A global market report released on October 30, 2026, profiles leading companies in epigenetic reprogramming longevity therapies, including Retro Biosciences, Altos Labs, and NewLimit. The report forecasts the capture of $16.14 billion in AI and cell reprogramming growth, highlighting the sector's rapid expansion.
NAD+ Precursor Efficacy A Nature Metabolism study confirmed that both NMN and NR double circulating NAD+ levels within just 14 days. While this mechanistic effect is solid, the clinical translation to healthspan extension remains under investigation, with senolytics showing early signals in Alzheimer's but disappointing results in bone health.
Clinical Trials & Intervention Updates
Rapamycin and Senolytic Trials The longevity research landscape in 2026 is defined by landmark clinical trials for senolytics and rapamycin. A fisetin trial for blood-vessel function in 136 older adults was registered in October 2026. Additionally, data indicates a 14% rise in the lifespan of female mice given rapamycin late in life (9% in males), measured by age at 90% mortality.
St. Jude Senolytic Trial A Phase 2 trial sponsored by St. Jude Children's Research Hospital (NCT07354620) is currently enrolling 110 participants to test senolytics for clearing senescent cells and reducing frailty in adult survivors of childhood cancer. This is noted as one of the most rigorous human senolytic trials to date, with an estimated completion in December 2026.
Industry & Biotech Watch
Dog Aging Project Receives $29M NIH Funding The Dog Aging Project has secured $29 million in funding from the NIH. This initiative aims to study aging in dogs to better understand human longevity, leveraging the natural genetic diversity and shorter lifespans of canines to accelerate research timelines.
FDA Clears NeuroXT’s AI Tool The FDA has cleared NeuroXT’s AI tool designed to assess Alzheimer's risk. This diagnostic advancement allows for earlier identification of neurodegenerative risks, potentially enabling earlier intervention strategies for healthy aging.
Seragy Raises $13.4M Longevity biotech startup Seragy raised $13.4 million to develop therapies targeting protein clumps, a key area of interest in preventing age-related diseases like Alzheimer's and Parkinson's.
Deep Dive: Intervention Evidence Check
Rapamycin and Fasting Mimicking Diets Current evidence supports the use of rapamycin as a senomorphic that modulates the Senescence-Associated Secretory Phenotype (SASP) rather than removing senescent cells. While animal models show clear lifespan extension, human data is still emerging. A notable trial (NCT07354620) combines intermittent rapamycin with a Prolon fasting-mimicking diet to move aging biomarkers. While small and early, it represents a real-world test of the popular "rapamycin-plus-fasting" stack.
NAD+ Precursors (NMN/NR) The mechanistic evidence for NMN and NR raising NAD+ levels is strong, with studies confirming a doubling of circulating levels in short timeframes. However, the field notes that while the data is "mechanistically solid," it remains "clinically unfinished," meaning the direct link to extended human healthspan is not yet definitively proven in large-scale trials.
What to Watch Next
- CTAD 2026 Conference: Eisai and Voyager are scheduled to present significant data on Alzheimer's and tau therapies at the Clinical Trials on Alzheimer's Disease (CTAD) conference.
- Rivus Animal Data: Rivus Pharmaceuticals is expected to show animal data on a muscle-sparing GLP-1, a critical development for maintaining lean mass during weight loss interventions.
- Nature Aging Forum: A Nature Forum in Paris on November 19, 2026, will convene researchers to explore how nutrition shapes healthy aging across the human lifespan.
Reader Action Items
- Monitor MRI Sleep Studies: A recent MRI study of 14,031 adults ties sleep quality directly to belly fat, reinforcing the importance of sleep hygiene for metabolic health and longevity.
- Explore NAD+ Testing: With NMN and NR confirmed to raise NAD+ levels, readers interested in these supplements should consider discussing baseline and post-supplementation NAD+ testing with their healthcare providers to verify efficacy.
- Follow the Dog Aging Project: Keep an eye on updates from the newly funded Dog Aging Project, as findings from canine studies often precede human clinical applications.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
